Coronavirus vaccine update: The month of December has kicked-off with a good news - Today, the United Kingdom became the first country to approve a vaccine against coronavirus, which has killed 1,487,701 people across the globe and has infected over 64 million. UK's approval of Pfizer/BioNTech vaccine has paved the way for mass vaccinations, which will begin from next week. The vaccine claims to offer up to 95 per cent protection against corona.
Other than Pfizer, Moderna vaccine candidate is said to be 94.5% effective at preventing Covid and is likely to be approved for emergency rollout in the US in few days. Meanwhile, India's 'Covaxin', Oxford-Astrazeneca, Johnson & Johnson, Russia's Sputnik V Covid-19 vaccones have shown promising result at different stages of trial.
Take a look at Covid vaccine progress across the world, including India
1. Pfizer coronavirus vaccine update: UK set to rollout Pfizer/BioNtech Covid-19 vaccine
The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, paving the way for mass vaccinations against the deadly novel coronavirus. The British regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), says the jab, which claims to offer up to 95 per cent protection against COVID-19 illness, is safe for roll out.
The joint vaccine, produced by American pharmaceutical giant Pfizer and German biotech firm BioNTech, had recently claimed trials suggested it works well in people of all ages, races and ethnicities.
The UK is expected to receive a total of 40 million doses by the end of 2021, enough to vaccinate up to a third of the population.
2. Russia coronavirus update
Vladimir Putin orders Russia to start mass vaccinations against Covid-19 next week
President Vladimir Putin ordered Russian authorities on Wednesday to begin mass voluntary vaccinations against Covid-19 next week. Russia will have produced 2 million vaccine doses within the next few days, Putin said. Russia said last month that its Sputnik V jab was 92% effective at protecting people from coronavirus according to interim results.
“Let’s agree on this - you will not report to me next week, but you will start mass vaccination...let’s get to work already,” Putin told Deputy Prime Minister Tatiana Golikova.
3. Dr Reddy's, RDIF commence clinical trials for Sputnik V Covid-19 vaccine in India
Dr Reddy's Laboratories and Russian Direct Investment Fund (RDIF) on Tuesday said they have commenced adaptive phase 2/3 clinical trials for the Sputnik V Covid-19 vaccine in India. The trials have commenced after receiving the necessary clearance from the Kasauli-based Central Drugs Laboratory, they added.
4. Oxford vaccine controversy in India
Covid vaccine won't be released unless proven safe, assures SII
In the midst of a controversy surrounding a 40-year-old Chennai subject in the clinical trial of the Oxford-AstraZeneca vaccine falling seriously ill and demanding Rs 5 crore in damages from Pune-based Serum Institute of India (SII), the firm on Tuesday assured that its vaccine candidate Covishield would not be released for mass use unless proven ‘immunogenic and safe’.
5. Mexico set to sign deal with Pfizer
Mexico's government is set to sign a contract on Wednesday with pharmaceutical company Pfizer for the delivery of its coronavirus vaccine.
Pfizer has submitted the details about its vaccine to Mexico's health regulator, Cofepris, and the country's foreign minister last month said the government expects the vaccine to reach Mexico in December.
Mumbai-based drugmajor Wockhardt said it is in talks with global vaccine makers for contract manufacturing drug substances for making vaccines as well as do the fill and finish doses out of its Indian site which has a capacity for one billion doses annually.
Drug substances are the raw material for making vaccines.
7. Pfizer-BioNTech apply for EU emergency authorisation for Covid-19 vaccine
Pfizer Inc and BioNTech have applied to the European drugs regulator for conditional authorization of their COVID-19 vaccine, following similar steps in the United States and Britain, the companies said on Tuesday. The application to the European Medicines Agency (EMA) comes after the companies applied for U.S. approval on Nov. 20, taking them a step closer to launching their vaccine.
8. China gave Covid-19 vaccine candidate to North Korea's Kim: US analyst
China has provided North Korean leader Kim Jong Un and his family with an experimental coronavirus vaccine, a U.S. analyst said on Tuesday, citing two unidentified Japanese intelligence sources. Harry Kazianis, a North Korea expert at the Center for the National Interest think tank in Washington, said the Kims and several senior North Korean officials had been vaccinated.
9. India coronavirus vaccine latest news
'Indian govt never talked of vaccinating entire population with Covid-19 vaccine'
There was never any talk of inoculating the whole population of the country with Covid-19 vaccine, the Centre said on Tuesday said. Union Health Secretary Rajesh Bhushan said there was never a talk about inoculating the whole population of the country with COVID-19 vaccine. "I just want to make this clear that the government has never spoken about vaccinating the entire country. It's important that we discuss such scientific issues, based on factual information only and then analyse it," said Bhushan.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU